In this week's episode of "The Top Line," we look at factors driving the continuing decline of flu vaccination rates in the U.S. and beyond. 

Fierce Pharma’s Zoey Becker chats with Gregg Sylvester, M.D., Chief Health Officer at CSL Seqirus, to get insight on what we might expect to see from this upcoming flu season. He also explains efforts to increase vaccine uptake through awareness and education campaigns.  

To learn more about the topics in this episode: 
Flu vaccine makers CSL Seqirus, Sanofi and GSK kick off initial shipments ahead of upcoming season
CDC starts 'Wild to Mild' campaign to reverse falling flu vaccine use in key groups
American Lung Association, Sanofi urge high-risk communities to grab their flu shots in 'United Against Flu' campaign

In this week's episode of "The Top Line," we look at factors driving the continuing decline of flu vaccination rates in the U.S. and beyond. 
Fierce Pharma’s Zoey Becker chats with Gregg Sylvester, M.D., Chief Health Officer at CSL Seqirus, to get insight on what we might expect to see from this upcoming flu season. He also explains efforts to increase vaccine uptake through awareness and education campaigns.  
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercepharma.com/pharma/flu-vaccine-makers-csl-seqirus-sanofi-and-gsk-kick-initial-shipments-ahead-upcoming">Flu vaccine makers CSL Seqirus, Sanofi and GSK kick off initial shipments ahead of upcoming season</a></li>
<li><a href="https://www.fiercepharma.com/pharma/cdc-starts-wild-mild-campaign-reverse-falling-flu-vaccine-use-key-groups">CDC starts 'Wild to Mild' campaign to reverse falling flu vaccine use in key groups</a></li>
<li><a href="https://www.fiercepharma.com/marketing/american-lung-association-sanofi-urge-high-risk-communities-grab-their-flu-shots-its">American Lung Association, Sanofi urge high-risk communities to grab their flu shots in 'United Against Flu' campaign</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Driving flu vaccine uptake in the post pandemic era

Biotherapeutics are transforming healthcare for over 350 million patients globally, tackling everything from cancer and diabetes to rare diseases.

Human embryonic kidney (HEK) 293 cells play a key role in the manufacturing of many of these life-changing products. However, they are not without their challenges.

In this episode of The Top Line, sponsored by Bio-Rad, Dipika Gurnani, Global Product Manager at Digital Biology Group, discusses the critical need to accurately quantify HEK293 DNA in biotherapeutics to ensure patient safety and regulatory compliance.

Gurnani highlights the risks of residual DNA integrating into a patient's genome, potentially causing cancer or genetic abnormalities. She also addresses the limitations of traditional quantification methods like qPCR, which can be time-consuming and prone to errors.

We also look at some key innovations in the field, such as Bio-Rad’s Vericheck ddPCR HEK293 Residual DNA Quantification Kit that can minimize false positives by specifically targeting HEK293 DNA.

For deeper insights into these challenges and innovations, listen to the full episode.

Biotherapeutics are transforming healthcare for over 350 million patients globally, tackling everything from cancer and diabetes to rare diseases.
Human embryonic kidney (HEK) 293 cells play a key role in the manufacturing of many of these life-changing products. However, they are not without their challenges.
In this episode of The Top Line, sponsored by Bio-Rad, Dipika Gurnani, Global Product Manager at Digital Biology Group, discusses the critical need to accurately quantify HEK293 DNA in biotherapeutics to ensure patient safety and regulatory compliance.
Gurnani highlights the risks of residual DNA integrating into a patient's genome, potentially causing cancer or genetic abnormalities. She also addresses the limitations of traditional quantification methods like qPCR, which can be time-consuming and prone to errors.
We also look at some key innovations in the field, such as Bio-Rad’s Vericheck ddPCR HEK293 Residual DNA Quantification Kit that can minimize false positives by specifically targeting HEK293 DNA.
For deeper insights into these challenges and innovations, listen to the full episode.

In this episode sponsored by Bio-Rad, Dipika Gurnani of Digital Biology Group outlines the challenges and innovations for quantifying HEK 293 DNA.

The Crucial Role of HEK293 DNA Quantification in Biotherapeutics [Sponsored by Bio-Rad Laboratories]

For the last 40 years, when federal legislation was ambiguous or left an administrative gap, courts were required to defer to the interpretation of agencies. This stipulation, called the Chevron deference, gave agencies room to advance their regulatory priorities. 

The Supreme Court overturned the doctrine in June, bringing significant implications for the healthcare industry and federal regulators like the FDA. 

In this week's episode of "The Top Line," Fierce Pharma’s Kevin Dunleavy chats with Project Farma President Anshul Mangal about the potential impact on the biopharma industry. 

To learn more about the topics in this episode: 
Supreme Court overrules Chevron deference, dealing blow to federal healthcare agencies
The Supreme Court just limited federal power. Healthcare is feeling the shock waves
How Chevron's demise could impact employers, purchasers and health payers

For the last 40 years, when federal legislation was ambiguous or left an administrative gap, courts were required to defer to the interpretation of agencies. This stipulation, called the Chevron deference, gave agencies room to advance their regulatory priorities. 
The Supreme Court overturned the doctrine in June, bringing significant implications for the healthcare industry and federal regulators like the FDA. 
In this week's episode of "The Top Line," Fierce Pharma’s Kevin Dunleavy chats with Project Farma President Anshul Mangal about the potential impact on the biopharma industry. 
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercehealthcare.com/regulatory/supreme-court-overrules-chevron-deference-dealing-blow-federal-healthcare-agencies">Supreme Court overrules Chevron deference, dealing blow to federal healthcare agencies</a></li>
<li><a href="https://www.fiercehealthcare.com/regulatory/supreme-court-just-limited-federal-power-health-care-feeling-shockwaves">The Supreme Court just limited federal power. Healthcare is feeling the shock waves</a></li>
<li><a href="https://www.fiercehealthcare.com/regulatory/how-chevron-decision-could-impact-employers-purchasers-health-payers">How Chevron's demise could impact employers, purchasers and health payers</a></li>
</ul>

What Chevron’s overturn means for biopharma

The TROP2 antibody-drug conjugate race has heated up among three Big Pharma companies: Gilead Sciences, AstraZeneca and Merck. 

Fierce Pharma’s Angus Liu recently took a deep dive into the three TROP2 front-runners. In a feature article, he examined the strengths and potential challenges facing each candidate, as well as the considerations behind their extensive phase 3 programs and their various development strategies.

In this week’s episode of “The Top Line,” Fierce executive editor Eric Sagonowsky chats with Liu about his feature story on the three TROP2 front-runners.

To learn more about the topics in this episode:
3 Big Pharma companies, 33 phase 3 trials: The race for supremacy in an ADC field
ASCO: Gilead looks for silver lining in Trodelvy’s failed lung cancer trial. But will the FDA play ball?
AstraZeneca-Daiichi's Enhertu follow-up Dato-DXd unable to prove overall survival benefit in phase 3

The TROP2 antibody-drug conjugate race has heated up among three Big Pharma companies: Gilead Sciences, AstraZeneca and Merck. 
Fierce Pharma’s Angus Liu recently took a deep dive into the three TROP2 front-runners. In a feature article, he examined the strengths and potential challenges facing each candidate, as well as the considerations behind their extensive phase 3 programs and their various development strategies.
In this week’s episode of “The Top Line,” Fierce executive editor Eric Sagonowsky chats with Liu about his feature story on the three TROP2 front-runners.
To learn more about the topics in this episode:
<ul>
<li><a href="https://www.fiercepharma.com/pharma/3-big-pharma-companies-33-phase-3-trials-race-supremacy-adc-field">3 Big Pharma companies, 33 phase 3 trials: The race for supremacy in an ADC field</a></li>
<li><a href="https://www.fiercepharma.com/pharma/asco-gilead-looks-silver-lining-trodelvys-failed-lung-cancer-trial-will-fda-open-its-door">ASCO: Gilead looks for silver lining in Trodelvy’s failed lung cancer trial. But will the FDA play ball?</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/astrazeneca-daiichis-enhertu-follow-unable-prove-overall-survival-benefit-phase-3">AstraZeneca-Daiichi's Enhertu follow-up Dato-DXd unable to prove overall survival benefit in phase 3</a></li>
</ul>

Driving flu vaccine uptake in the post pandemic era

In 1 playlist(s)

The Top Line

Social links

Follow podcast

Recent clips